Preclinical development of FL-091, a novel NTSR1 targeting radionuclide drug conjugate for the treatment of NTSR1-positive cancers

被引：0
|
作者：
Zhang, J. [1 ]
Yang, J. [1 ]
Liu, F. [1 ]
Wong, N. C. L. [1 ]
Thrane, K. T. [2 ]
Hallund, M. W. [2 ]
Gronlund, R. V. [2 ]
机构：
[1] Full Life Technol, Shanghai, Peoples R China
[2] Minerva Imaging ApS, Olstykke, Denmark
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2024年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-676
引用
收藏
页码：S322 / S323
页数：2
相关论文
共 46 条
  • [41] Development of 5D3-DM1: A Novel Anti-Prostate-Specific Membrane Antigen Antibody-Drug Conjugate for PSMA-Positive Prostate Cancer Therapy
    Huang, Colin T.
    Guo, Xin
    Barinka, Cyril
    Lupold, Shawn E.
    Pomper, Martin G.
    Gabrielson, Kathleen
    Raman, Venu
    Artemov, Dmitri
    Hapuarachchige, Sudath
    MOLECULAR PHARMACEUTICS, 2020, 17 (09) : 3392 - 3402
  • [42] Targeting CD205-positive solid tumors with a novel antibody drug conjugate (ADC): OBT076/MEN1309 target expression and activity guides Ph1 trial design
    Kaplan, A.
    Attanasio, N.
    Bisht, A.
    Deban, L.
    Lou, S. L.
    Berry, J.
    Dusek, R.
    Boyd, R.
    Binaschi, M.
    Pellacani, A.
    Zhukovsky, E.
    Rohlff, C.
    Fandi, A.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E47 - E47
  • [43] Preclinical efficacy and safety of M9140, a novel antibody-drug conjugate (ADC) with topoisomerase 1 (TOP1) inhibitor payload targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)-expressing colorectal tumors
    Raab-Westphal, Sabine
    Hart, Felix
    Sloot, Willem
    Shan, Min
    Rasche, Nicolas
    Amendt, Christiane
    Anderl, Jan
    CANCER RESEARCH, 2024, 84 (06)
  • [44] ADK-VR2, a cell line derived from a treatment-naive patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged NSCLC
    Ruzzi, Francesca
    Angelicola, Stefania
    Landuzzi, Lorena
    Nironi, Elena
    Semprini, Maria Sofia
    Scalambra, Laura
    Altimari, Annalisa
    Gruppioni, Elisa
    Fiorentino, Michelangelo
    Giunchi, Francesca
    Ferracin, Manuela
    Astolfi, Annalisa
    Indio, Valentina
    Ardizzoni, Andrea
    Gelsomino, Francesco
    Nanni, Patrizia
    Lollini, Pier-Luigi
    Palladini, Arianna
    TRANSLATIONAL LUNG CANCER RESEARCH, 2022, : 2216 - 2229
  • [45] DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance
    Takegawa, Naoki
    Nonagase, Yoshikane
    Yonesaka, Kimio
    Sakai, Kazuko
    Maenishi, Osamu
    Ogitani, Yusuke
    Tamura, Takao
    Nishio, Kazuto
    Nakagawa, Kazuhiko
    Tsurutani, Junji
    INTERNATIONAL JOURNAL OF CANCER, 2017, 141 (08) : 1682 - 1689
  • [46] Targeting HER2-positive metastatic breast cancer with ARX788, a novel anti-HER2 antibody-drug conjugate in patients whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens.
    Lu, Janice M.
    Kalinsky, Kevin
    Tripathy, Debu
    Sledge, George W.
    Gradishar, William John
    O'Regan, Ruth
    O'Shaughnessy, Joyce
    Modi, Shanu
    Park, Haeseong
    McCartney, Amelia
    Frentzas, Sophia
    Shannon, Catherine M.
    Eek, Richard Wilhelm
    Martin, Miguel
    Curigliano, Giuseppe
    Jerusalem, Guy Heinrich Maria
    Huang, Chiun-Sheng
    Press, Michael F.
    Tolaney, Sara M.
    Hurvitz, Sara A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345